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questions should provide a hearty agenda for future research.
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Accepted 29 July 2013Many within the transplantation community perceive
that allogeneic hematopoietic cell transplantation (HCT) is
an underutilized approach among appropriate adult patients
who potentially may beneﬁt from this procedure. This
perception is particularly true for patients who do not have
an HLA-identical sibling donor and for whom the graft must
come from unrelated donors or umbilical cord blood (UCB)
units (henceforth, both are referred to as URD). In this issue,
Yao et al. [1] present a study that quantiﬁes this view; after
accounting for comorbidities, pretransplantation treatment
mortality, and patient preferences, only one quarter of
patients in whom URD HCT is indicated actually receive it.
The utilization for speciﬁc diseases ranged from 11% for
myeloma to 54% for chronic myeloid leukemia, 2 diseases for
which indications for HCT have dropped. In the present era,when it appears that nearly all patients can ﬁnd a suitable
donor for transplantation, including haploidentical HCT [2],
this low percentage is a staggering statistic. Further, Yao et al.
[1] show that among acute leukemia patients, two thirds
underwent transplantation only in late stage disease, a point
in time when survival outcomes are inferior when compared
with earlier use of HCT [3,4].
The National Marrow Donor Program (NMDP) has access
to 21 million potential donors worldwide, including 11
million through its Be The Match Registry. This potential
graft inventory also includes more than 600,000 cry-
opreserved UCB units. The likelihood of identifying an adult
donor, unfortunately, reﬂects race, as white patients have
a 93% likelihood of ﬁnding a match, whereas for minority
ethnic and racial groups, the chance is less; the lowest like-
lihood is for blacks, at 66%. On the other hand, a suitable UCB
unit can be found for transplantation for most patients in
whom a matched adult donor cannot be found. The NMDP
estimates that approximately 12,000 patients in the United
States need an URD transplantation each year. An early step
in this process is the initiation of a “formal search”, which
usually indicates a deﬁnitive intent on behalf of the trans-
plantation center to move ahead with an URD HCT. In the
2012 ﬁscal year, a formal search was requested for only 7400
patients, just 62% of the need. Furthermore, only 60% of
patients for whom a formal search was initiated actually
proceeded to transplantation.
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transplantation should be straightforward, via a timely and
seamless referral to a transplantation center. In real life,
however, a “funnel effect” occurs, in which patients succes-
sively lose the opportunity to get to transplantation as they
go through different phases of their treatment. This
phenomenon occurs for both related and URD HCT, but is
much more prominent for the latter. Many factors contribute
to this funneling of URD HCT. Patients may not be referred to
a transplantation center for a consultation, or they may be
referred at an advanced disease stage, when transplantation
is no longer feasible or effective. First and foremost, however,
is the absence or late referral of patients to transplantation
centers by our hematology-oncology colleagues. Mawad
et al. [5] from Seattle recently reported encouraging results
of using allogeneic HCT to treat ﬁrst complete remission
acute myeloid leukemia patients. They employed several
novel approaches including alternative donors (some of
whom were HLA-mismatched), diverse graft types (such as
UCB units), relaxed selection criteria, and less intensive
pretransplantation conditioning regimens (as opposed to
more conventional intensity). Their data demonstrated that
a strong resolve and various creative approaches facilitated
many subjects to proceed to potentially curative therapy.
Despite such examples illustrating an improvement in the
transplantation rate for eligible patients and improved
patient outcome, referring physicians may not refer patients
because of their negative perceptions about risks, efﬁcacy,
and toxicity of URD HCT, especially in older patients [6].
Although HCT still is associated with mortality, Gooley
et al. [7] found that over the past decade, the hazard of death
related to allogeneic HCT has been reduced substantially and
long-term survival rates have increased because of reductions
in organ damage, infection, and severe acute graft-versus-
host disease. Undoubtedly, several patient-related barriers
to access exist, such as disparities in socioeconomic status,
insurance coverage, distance fromtransplantation center, and
cultural preferences [8-10]. Transplantation centers may
contribute to this issue, as these institutionsmaynot have the
infrastructure and capacity to accommodate the growing
demand for transplantation in their area, or they may not
have experience in conducting certain types of trans-
plantation, ie, UCB HCT. In some instances, restrictions
placed by public and private payers also may prevent
patients from receiving a transplant (eg, lack of Medicare
coverage for allogeneic HCT for lymphoma and myeloma
patients, and until recently, myelodysplastic syndromes).
Issues with donor availability, such as attrition or donor
medical issues, occasionally can delay transplantation.
How can we close this gap? Most importantly, we need
more investigative efforts to understand patient, provider,
and healthcare system barriers to URD HCT and to develop
interventions to mitigate them. Until research ﬁndings
become available, we can continue to build the evidence base
for the efﬁcacy of HCT and maintain institutional and group
(eg, Center for International Blood and Marrow Transplant
Research and Blood and Marrow Transplant Clinical Trials
Network) efforts to improve patient outcomes further
through innovative preclinical research and clinical trials. We
need to support and augment the efforts of transplantation
centers, the American Society of Blood and Marrow Trans-
plantation and the NMDP to continue to educate our non-
transplantation colleagues about the importance of timelyreferral for a transplantation consultation. The NMDP, in
collaboration with the American Society of Blood and
Marrow Transplantation and other stakeholders, has con-
ducted a comprehensive evaluation of personnel and infra-
structure challenges to HCT and several projects from this
initiative will address these capacity issues [11,12]. Health
care disparities need to be addressed, and although more
research is conducted speciﬁcally for HCT recipients in this
area, we can translate knowledge gained from the cancer
disparities literature to our patients. The NMDP continues to
invest heavily in technology, processes, and infrastructure to
shorten the time from initiation of donor search to trans-
plantation. We also need to continue studies that show the
value of URD HCT as a treatment modality for various
diseases and age groups.
Findings by Yao et al. highlight the signiﬁcant amount of
work that still needs to be done to address several obstacles
to URD HCT. The onus to address these barriers rests mainly
on us, the transplantation community. We need to serve as
better advocates for our patients so that HCT can be made
available to all patients who can potentially beneﬁt from this
life-saving treatment.ACKNOWLEDGMENTS
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